Physician profile
Muhammad M Mohyuddin
NPI 1851719728
$5,895.71
in general payments reported to CMS, 2019-2025
22 companies · $3,536 in 2025
The $3,536 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.39 · 2020: $169 · 2021: $172 · 2022: $332 · 2023: $965 · 2024: $703 · 2025: $3,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106 · Travel and Lodging: $1,472 · Education: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.42 |
| Travel and Lodging | $1,472.23 |
| Education | $625.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,522.26 | 2023-2025 | Watchman Access System, Avvigo Guidance System, General - Vascular Access |
| Stryker Corporation | $1,010.43 | 2025 | Clottriever Bold Catheter, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abiomed | $695.02 | 2023-2025 | Impella |
| Abbott Laboratories | $610.90 | 2023-2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit, Assurity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $538.84 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $385.73 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Amgen INC. | $242.33 | 2021-2024 | Repatha |
| Pfizer INC. | $171.28 | 2019-2025 | |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Terumo Medical Corporation | $132.54 | 2025 | Glidewire, Optitorque, Metacross Otw |
| E.R. Squibb & Sons, L.L.C. | $128.03 | 2022-2023 | Camzyos |
| Alnylam Pharmaceuticals INC. | $53.11 | 2024-2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $49.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.94 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $35.48 | 2025 | Opsumit, Uptravi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $22.61 | 2022 | |
| Novo Nordisk INC | $22.27 | 2022 | |
| Impulse Dynamics (USA) INC. | $19.22 | 2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $18.63 | 2023 | Inpefa |
| Siemens Medical Solutions USA, INC. | $18.59 | 2022 | |
| Chiesi USA, INC. | $14.76 | 2025 | Cleviprex, Kengreal |
| Merck Sharp & Dohme LLC | $14.44 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mohyuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.